| Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile (NCT05192148) | Fondation Hôpital Saint-Joseph | 2021-11-30 |
| Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection (NCT04885946) | Christian Hvas | 2021-06-02 |
| Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) (NCT04305769) | University of Virginia | 2021-06-01 |
| Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases (NCT04698148) | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | 2021-02-08 |
| Natural History of Clostridioides Difficile Infection (NCT04801862) | Hospital Universitario de Valme | 2021-01-01 |
| Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection (NCT04138706) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2020-11-19 |
| Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea (NCT04567134) | Hanyang University Seoul Hospital | 2020-10-01 |
| ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection (NCT04247542) | Acurx Pharmaceuticals Inc. | 2020-03-06 |
| A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection (NCT04100603) | ProgenaBiome | 2020-03-02 |
| PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMA (NCT04259931) | Hospital Universitario de Cabuenes | 2020-03-01 |
| Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection (NCT04317963) | University of Illinois at Chicago | 2020-02-12 |
| The Dynamic Fluctuation of Donor Microbiota Affects the Prognosis of Fecal Microbiota Transplantation for C. Difficile Infection (NCT05703477) | Shanghai 10th People's Hospital | 2020-01-01 |
| Validation of a Prediction Score for Recurrent C. Difficile Infection: Implementation for Treatment Algorithm Strategies (NCT04187430) | Emilio Bouza | 2019-12-01 |
| Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™ (NCT05008640) | Toi Labs, Inc. | 2019-11-14 |
| Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence. (NCT04075422) | Fundacion SEIMC-GESIDA | 2019-10-01 |
| Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) (NCT04000555) | University of South Florida | 2019-09-01 |
| Fecal Microbiota Transplant for Primary CDI (NCT03795233) | Boston Medical Center | 2019-08-23 |
| Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) (NCT03931941) | Rebiotix Inc. | 2019-07-30 |
| Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile (NCT03827447) | Medical College of Wisconsin | 2019-07-17 |
| Fecal Transplantation for Primary Clostridium Difficile Infection (NCT03796650) | Oslo University Hospital | 2019-07-17 |
| Safety and Efficacy of Fecal Microbiota Transplantation (NCT04014413) | Chinese University of Hong Kong | 2019-07-15 |
| CDI Synbiotic Study (NCT04012788) | Hvidovre University Hospital | 2019-07-01 |
| FQ Restriction for the Prevention of CDI (NCT03848689) | University of Wisconsin, Madison | 2019-05-01 |
| The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation (NCT03621657) | University of Wisconsin, Madison | 2019-03-21 |
| Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection (NCT03788434) | Vedanta Biosciences, Inc. | 2019-02-08 |
| Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD (NCT03824795) | MGB Biopharma Limited | 2019-02-07 |
| Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI) (NCT03710694) | Da Volterra | 2018-10-31 |
| Fecal Microbiota Transplantation (FMT) for Clostridium Difficile (NCT03712722) | University of Aarhus | 2018-10-01 |
| Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection (NCT03586206) | Roma Tre University | 2018-09-15 |
| A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program (NCT03350711) | Emory University | 2018-09-13 |
| Clostridium Difficile Virulence Mechanism Study (CDVM Study) (NCT03654872) | Chinese University of Hong Kong | 2018-06-30 |
| COMBACTE-CDI Understanding the Burden of C. Difficile Infection (NCT03503474) | University of Leeds | 2018-06-11 |
| Fecal Microbiota Transplant (NCT04090346) | Methodist Health System | 2018-06-05 |
| Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients (NCT03030248) | Medical College of Wisconsin | 2018-06-01 |
| Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection (NCT02464306) | University of Colorado, Denver | 2018-06-01 |
| Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection (NCT03462459) | University of Wisconsin, Madison | 2018-05-21 |
| Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (NCT03497806) | Finch Research and Development LLC. | 2018-05-01 |
| Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) (NCT03182907) | Merck Sharp & Dohme LLC | 2018-03-27 |
| Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics (NCT03466502) | University of Nevada, Reno | 2018-03-08 |
| Use of Bismuth Subsalicylate in Clostridium Difficile Colitis (NCT03592082) | Bassett Healthcare | 2018-03-01 |
| TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment (NCT03388268) | Washington University School of Medicine | 2017-12-29 |
| MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI) (NCT02865616) | NuBiyota | 2017-10-27 |
| Fecal Microbiota Transplant National Registry (NCT03325855) | American Gastroenterological Association | 2017-09-20 |
| Treatment for Clostridium-difficile Infection With IMM529 (NCT03065374) | Immuron Ltd. | 2017-09-01 |
| Incidence and Economic Burden of Clostridium Difficile Infections (CDI) in the German Health Care System (IBIS) (NCT03141775) | University of Cologne | 2017-08-01 |
| The ICON Study: Outcomes After FMT for Patients With IBD and CDI (NCT03106844) | Brigham and Women's Hospital | 2017-08-01 |
| ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection (NCT03183128) | Seres Therapeutics, Inc. | 2017-07-10 |
| Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection (NCT03349268) | University of Michigan | 2017-07-07 |
| Oral Vancomycin for Preventing Clostridium Difficile Recurrence (NCT03200093) | Rochester General Hospital | 2017-06-08 |
| Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD) (NCT03105479) | Actelion | 2017-04-14 |
| Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains (NCT02968758) | Meridian Bioscience, Inc. | 2017-02-06 |
| Oral Vaccination Against Clostridium Difficile Infection (NCT02991417) | Simon M. Cutting | 2017-01-01 |
| Screening to Prophylax Against Clostridium Difficile Infection - (NCT02996487) | Corewell Health East | 2016-12-19 |
| Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection (NCT02686645) | Queen Elizabeth II Health Sciences Centre | 2016-12-01 |
| Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics (NCT02951702) | St. Luke's Hospital, Chesterfield, Missouri | 2016-11-01 |
| Fecal Microbiota Transplant by Oral Capsules With Lactobacilli for Recurrent Clostridium Difficile Infection (NCT03804736) | Universidad Autonoma de Nuevo Leon | 2016-11-01 |
| Treatment of Recurrent Clostridium Difficile Infection With RBX7455 (NCT02981316) | Mayo Clinic | 2016-11-01 |
| Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-Negatives (NCT03250104) | University Hospital of Cologne | 2016-11-01 |
| SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence (NCT02830542) | Seres Therapeutics, Inc. | 2016-08-01 |
| Protocol for Admission Toxigenic C. Difficile Surveillance (NCT04014608) | Endeavor Health | 2016-07-01 |
| Specific Carbohydrate Diet for Clostridium Difficile (NCT03925636) | David Suskind | 2016-06-08 |
| Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection (NCT02743234) | University of Aarhus | 2016-04-01 |
| Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir (NCT02707198) | St. Luke's Hospital of Duluth | 2015-11-01 |
| Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (NCT02589847) | Rebiotix Inc. | 2015-10-01 |
| Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection (NCT02395848) | McMaster University | 2015-07-01 |
| Gut Microbiota Changes After Fecal Microbiota Transplantation (NCT02557685) | The Miriam Hospital | 2015-06-01 |
| Evaluation of the Cost of a Nosocomial Infection With Clostridium Difficile (NCT03025672) | Lille Catholic University | 2015-04-01 |
| Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection (NCT02053350) | University of Virginia | 2015-04-01 |
| Freeze-dried, Capsulized FMT for RCDI (NCT02399618) | Jinling Hospital, China | 2015-03-01 |
| IMT for Primary Clostridium Difficile Infection (NCT02301000) | Oslo University Hospital | 2015-02-22 |
| Treatment of Initial Clostridium Difficile Infection (NCT03107169) | Universidad Autonoma de Nuevo Leon | 2015-02-01 |
| FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI (NCT02255305) | Endeavor Health | 2015-01-01 |
| FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment (NCT02570477) | Chinese University of Hong Kong | 2015-01-01 |
| Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile? (NCT02461901) | Professor Mark Wilcox | 2015-01-01 |
| A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) (NCT02784002) | Summit Therapeutics | 2014-12-01 |
| Effect of Acid Suppression Medication on Pediatric Microbiome (NCT02016820) | Columbia University | 2014-11-01 |
| Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection (NCT02237859) | Corewell Health West | 2014-08-01 |
| Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123. (NCT02106338) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-06-01 |
| A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD) (NCT02092935) | Summit Therapeutics | 2014-04-01 |
| Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection (NCT02326636) | University of California, Irvine | 2014-04-01 |
| Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea (NCT01987895) | Actelion | 2014-03-27 |
| Prospective Observational Study of Clostridium Difficile Infection in Asian Pacific Countries (NCT02223715) | Otsuka Pharmaceutical Co., Ltd. | 2014-03-01 |
| Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile (NCT03562741) | Krunal Patel | 2014-01-16 |
| Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (NCT01983683) | Actelion | 2013-12-12 |
| Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis (NCT03268213) | Stony Brook University | 2013-11-01 |
| Transplantation of Fecal Microbiota for Clostridium Difficile Infection (NCT01958463) | Tel-Aviv Sourasky Medical Center | 2013-11-01 |
| Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea (NCT01972932) | Bio-K Plus International Inc. | 2013-11-01 |
| Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis (NCT01942447) | University Hospital Tuebingen | 2013-10-01 |
| Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum (NCT01914731) | Massachusetts General Hospital | 2013-08-01 |
| Pathogenic Mechanisms in C Diff Infection and Colitis (NCT01930032) | Beth Israel Deaconess Medical Center | 2013-08-01 |
| Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT) (NCT01842347) | Medical College of Wisconsin | 2013-08-01 |
| Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection (NCT01887912) | Sanofi Pasteur, a Sanofi Company | 2013-07-30 |
| Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan (NCT01896830) | Sanofi Pasteur, a Sanofi Company | 2013-07-01 |
| Fecal Microbiota Transplantation for C Diff Infection (NCT01905709) | Englewood Hospital and Medical Center | 2013-07-01 |
| The Impact of Proton Pump Inhibitors on the Fecal Microbiome (NCT01822977) | Mayo Clinic | 2013-03-01 |
| Predictive Value of the Immune Response of the Host in Clostridium Difficile Infections (NCT01946750) | Versailles Hospital | 2012-12-01 |
| Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea (NCT01670149) | University of Nottingham | 2012-12-01 |
| Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum (NCT01704937) | Massachusetts General Hospital | 2012-11-01 |
| Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin (NCT01818141) | Hartford Hospital | 2012-10-17 |
| Fidaxomicin to Prevent Clostridium Difficile Colonization (NCT01552668) | Washington University School of Medicine | 2012-09-01 |